We are advancing a flexible CAR T‑cell platform designed to precisely tune therapeutic persistence—from transient to durable expression—using proprietary nucleic acid formats and lipid nanoparticle delivery. By enabling both ex vivo engineering and in vivo administration, our approach aims to simplify translation to the clinic while expanding the reach of cell therapies across various indications with high medical need.
Current therapeutic focus
Combining forces with T-CURX to unlock the next generation of cell therapies
